elafibranor   Click here for help

GtoPdb Ligand ID: 11135

Synonyms: GFT-505 | GFT505 | Iqirvo®
Approved drug PDB Ligand
elafibranor is an approved drug (EMA & FDA (2024))
Compound class: Synthetic organic
Comment: Elafibranor (GFT-505) is a PPARα/δ agonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 88.9
Molecular weight 384.14
XLogP 4.97
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
Isomeric SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
InChI InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
InChI Key AFLFKFHDSCQHOL-IZZDOVSWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Elafibranor was advanced into clinical development by Genfit, as a therapuetic for nonalcoholic steatohepatitis (NASH) [4]. Phase 1/2 trials confirmed the potential efficacy of elafibranor, and specific adverse safety signals were not detected in these studies [2-3]. Interim (futility) analysis of Phase 3 trial data, concluded that elafibranor was not better than placebo at improving NASH symptoms without worsening fibrosis, and development for NASH was terminated in mid-2020. However, elafibranor was repositioned as a treament for primary biliary cholangitis and was granted FDA approval for this indication in June 2024 [1], and EMA authorisation in Sepetmber 2024, and it has since been authorised for use in other countries too.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01261494 Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus Phase 2 Interventional Genfit
NCT00001693 Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers Phase 1 Interventional National Institutes of Health Clinical Center (CC) 3
NCT01271751 Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity Phase 2 Interventional Genfit 3
NCT02704403 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Phase 3 Interventional Genfit As of July 2020 this trial was being closed down, as the drug was unlikely to show efficacy.